On July 25, the American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) jointly released resources to help research sites increase the racial and ethnic equity, diversity, and inclusion (EDI) in cancer clinical trials.
The Just ASK™ Training Program and Site Self-Assessment are available free-of-charge and represent a full and complementary set of resources that can help research sites address barriers to participation in cancer clinical trials among racial and ethnic populations that have been historically underrepresented.
The availability of the Just ASK™ Training Program and Site Self-Assessment follows the recent publication of the ASCO-ACCC Research Statement “Increasing Racial and Ethnic Diversity in Cancer Clinical Trials,” which outlines specific actions for individual stakeholders in the cancer clinical trial ecosystem to increase diversity in research participation. These recommendations—which are summarized in this illustration—focus on key areas that address barriers to cancer clinical trials.
The three resources directly address some of the recommendations in the Research Statement.
An annotated reference list of detailed strategies and resources is also available online. The list is not exhaustive. It is intended to provide examples of strategies for research sites to increase EDI in cancer clinical trials and to stimulate interest in research to establish more evidence-based strategies that result in increased participation of patients historically underrepresented in clinical trials.
The development and release of these resources is an important milestone in the ASCO-ACCC Initiative to Increase Racial and Ethnic Diversity in Clinical Trials. The initiative is led by a steering group of EDI experts, patient advocates, and other stakeholders. ASCO and ACCC formed a Patient Partners Advisory Group, which also informs the work of the collaboration, and includes cancer research advocates who represent racial and ethnic minority populations. The steering group sought to answer the call from the oncology community for tangible resources to help improve representation in cancer clinical trials – as evidenced by the eager involvement of 75 research sites in the pilot study. With the Research Site Self-Assessment, Training Program, Facilitation Guide, and Research Statement recommendations, it is ASCO and ACCC’s hope that sites feel supported and empowered to make change.
For more information on this project, please contact the ACCC Provider Education department.
ASCO and the Association of Community Cancer Centers (ACCC) hosted a joint virtual discussion about new resources to help diversify participation in cancer clinical trials. ASCO and ACCC have been collaborating to develop solutions to address participation disparities since 2020, and recently released two manuscripts detailing the results from a pilot program that led to the development and release of two free, online resources for cancer research sites.
ASCO-ACCC EDI Research Site Self-Assessment
This quality improvement tool helps clinical trial sites and research teams identify opportunities to improve EDI in clinical trials while doing an internal review of existing policies, programs, and procedures that offer evidence-based strategies to improve the diversity of trial participants.
An online implicit bias training program that presents the broader context of structural and systemic racism, the role of implicit bias in clinical trial selection, vignettes with real-world examples of implicit bias, and guidance for mitigating disparities in cancer research settings.
Just ASK™: How one healthcare system is operationalizing this implicit bias program to ensure equitable access to clinical trials.
Oncology Issues, V38-N2
To facilitate fruitful discussions with staff around implicit bias, this Just Ask™ Training Facilitation Guide has been developed to identify feasible action steps to support implementation of a Just Ask™ strategy in your research site or cancer program or practice.
The American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) jointly released recommendations to engage the entire cancer clinical trial ecosystem in expanding the participation of underrepresented individuals in research that advances progress against cancer and increases the equity, diversity, and inclusion (EDI) of cancer clinical trials.
Clinical Trials: Real-World Data Plays Early Role in Efforts to Increase Diversity
Regulatory News, Sep 5, 2022
Advances in Site Self-Assessment Tools Aim to Bolster Equity in Clinical Trials
OncLive, Aug 4, 2022
Diversify Your Cancer Clinical Trials with New Recruitment and Retention Resources
ACCC, Jul 25, 2022
Dr. Randall A. Oyer: Clinical Trials Must Be Accessible to Everyone
AJMC, June 1, 2022
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Journal of Clinical Oncology, May 19, 2022
UVA Joins National Effort to Increase Minority Representation in Cancer Clinical Trials
UVAHealth, Oct 14, 2021
Virginia Cancer Specialists Participating in National Pilot Project to Increase Diversity in Cancer Treatment Trials
Virginia Cancer Specialists, Oct 11, 2021
Increasing diversity in clinical trials can save lives. Here's how hospitals are doing that.
Tampa Bay News, Oct 8, 2021
SKCC to Participate in National Pilot Project to Increase Diversity in Cancer Treatment Trials
Sidney Kimmel Cancer Center, Sep 22,2021
HDFCCC Participating in National Pilot Project to Increase Diversity in Cancer Treatment Trials
UCSF Helen Diller Family Comprehensive Cancer Ctr., Sep 21, 2021
Masonic Cancer Center invited to participate in a ASCO/ACCC diversity-based pilot project
Masonic Cancer Center, Sep 20, 2021
Oncology Practices Nationwide Show High Interest in Diversifying Cancer Clinical Trials
July 15, 2021
ASCO & ACCC Join Forces to Increase Participation of Racial and Ethnic Minority Populations in Cancer Treatment Trials
May 3, 2021
ASCO-ACCC Piloting Test Tools to Diversify Cancer Clinical Trials
Jul 21, 2020